Skip to main content

Advertisement

SpringerLink
Log in

Progestin-Only Contraception and Bone Health

  • Family Planning (A Burke, Section Editor)
  • Published:
Current Obstetrics and Gynecology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Progestin-only contraceptive methods are important and effective options for women trying to prevent unintended pregnancy. There is concern about progestin-only methods and bone health, particularly for depot medroxyprogesterone acetate (DMPA), because progestin-only methods can lower estradiol levels through ovarian suppression. This is of particular concern for adolescents building bone and perimenopausal women heading towards menopause.

Recent Findings

DMPA does cause temporary bone loss, but this is reversible after discontinuation. Evidence is limited as to whether the decreased bone density and subsequent reversal that is seen with DMPA use leads to an increased risk of fracture in the future. Two observational studies indicate a weak association between DMPA use and fracture risk. Progestin-only implants, pills, and the intrauterine device do not have an impact on bone mineral density or fracture risk.

Summary

Use of DMPA or any other progestin-only method should not be restricted due to a theoretical risk of fractures when reproductive-age women face the very real risk of pregnancy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Da Silva VN, Fiorelli LNM, da Silva CC, Kurokawa CS, Goldberg TBL. Do metabolic syndrome and its components have an impact on bone mineral density in adolescents? Nutrition and Metabolism. 2017;14:1–7.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Chen FP, Wang KC, Huang JD. Effect of estrogen on the activity and growth of human osteoclasts in vitro. Taiwan J Obstet Gynecol. 2009;48:350–5.

    Article  PubMed  Google Scholar 

  3. Clarke BL, Khosla S. Female reproductive system and bone. Archives Biochemistry and Biophysics. 2010;503:118–28.

    Article  CAS  Google Scholar 

  4. Lindsay R, Hart DM, Aitken JM, MacDonald EB, Anderson JB, Clarke AC. Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet. 1976;1:1038–41.

    Article  CAS  PubMed  Google Scholar 

  5. Nappi C, Bifulco G, Tommaselli GA, Gargano V, DiCarlo C. Hormonal contraception and bone metabolism: a systematic review. Contraception. 2012;86:606–21.

    Article  CAS  PubMed  Google Scholar 

  6. Cundy T, Evans M, Roberts H, Wattie D, Ames R, Reid IR. Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ. 1991;303:13–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. McClung MR. The relationship between bone mineral density and fracture risk. Curr Osteoporos Rep. 2005;3:57–63.

    Article  PubMed  Google Scholar 

  8. Watts NB, Ettinger B, LeBoff MS. Perspective: FRAX facts. J Bone Min Research. 2009;24:975–9.

    Article  Google Scholar 

  9. Cohen A, Shane E. Evaluation and management of the premenopausal woman with low BMD. Curr Osteoporos Rep. 2013;11:276–85.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Melton 3rd LJ, Amadio PC, Crowson CS, O’Fallon WM. Long-term trends in the incidence of distal forearm fractures. Osteoporosis Int. 1998;8:341–8.

    Article  Google Scholar 

  11. Hui SL, Slemenda CW, Johnston Jr CC. Age and bone mass as predictors or fracture in a prospective study. J Clin Invest. 1988;81:1804–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Grimes DA, Schultz KF, Raymond EG. Surrogate end points in women’s health research: science, protoscience, and pseudoscience. Fertil and Steril. 2010;93:1731–4.

    Article  Google Scholar 

  13. Trussell J. Contraceptive failure in the United States. Contraception. 2011;83:397–404.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Mishell Jr DR. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med. 1996;41:381–90.

    CAS  PubMed  Google Scholar 

  15. Curtis KM, Martins SL. Progestogen-only contraception and bone mineral density: a systematic review. Contraception. 2006;73:470–87.

    Article  CAS  PubMed  Google Scholar 

  16. Cundy T, Cornish J, Roberst H, Elder H, Reid IR. Spinal bone density in women using depot medroxyprogesterone contraception. Obstet Gynecol. 1998;92:569–73.

    CAS  PubMed  Google Scholar 

  17. Berenson AB, Radecki CM, Grady JJ, Ricker VI, Thomas A. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstet Gynecol. 2001;98:576–82.

    CAS  PubMed  Google Scholar 

  18. Wanichsetakul P, Kamudhamas A, Watanaruangkovit P, Siripakarn Y, Visutakul P. Bone mineral density at various anatomic bone sites in women receiving oral contraceptives and depot-medroxyprogesterone acetate for contraception. Contraception. 2002;65:407–10.

    Article  CAS  PubMed  Google Scholar 

  19. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology. 2002;13:581–7.

    Article  PubMed  Google Scholar 

  20. Berenson AB, Breitkopf CR, Grady JJ, Rickert VI, Thomas A. Effects of hormonal contraception on bone mineral density after 24 months of use. Obstet Gynecol. 2004;103:899–906.

    Article  CAS  PubMed  Google Scholar 

  21. Clark MK, Sowers M, Levy B, Nichols S. Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate. Fertil Steril. 2006;86:1466–74.

    Article  CAS  PubMed  Google Scholar 

  22. Clark MK, Sowers MR, Nichols S, Levy B. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fertil Steril. 2004;82:1580–6.

    Article  CAS  PubMed  Google Scholar 

  23. Kaunitz AM, Miller PD, Rice VM, Ross D, McClung MR. Bone mineral density in women aged 25–35 years receiving depot medroxyprogesterone actetate: recovery following discontinuation. Contraception. 2006;74:90–9.

    Article  CAS  PubMed  Google Scholar 

  24. Cromer BA, Bonny AE, Stager M, Lazebnik R, Ziegler J, Camlin-Shingler K, Secic M. Bone mineral density in adolescent females using injectable or oral contraceptives: a 24–month prospective study. Fertil Steril. 2008;90:2060–7.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Cromer BA, Blair JM, Mahan JD, Zibners L, Naumovski Z. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr. 1996;129:671–6.

    Article  CAS  PubMed  Google Scholar 

  26. Lara-Torre E, Edwards CP, Perlman S, Hertweck SP. Bone mineral density in adolescent females using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol. 2004;17:17–21.

    Article  PubMed  Google Scholar 

  27. Busen NH, Britt RB, Rianon N. Bone mineral density in a cohort of adolescent women using depot medroxyprogesterone acetate for one to two years. J Adolesc Health. 2003;32:257–9.

    Article  PubMed  Google Scholar 

  28. Harel Z, Johnson CC, Gold MA, Cromer B, Peterson E, Burkman R, Stager M, Brown R, Bruner A, Coupey S, Hertweck P, Bone H, Wolter K, Nerson A, Marshall S, Bachrach LK. Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections. Contraception. 2010;81:281–91.

    Article  CAS  PubMed  Google Scholar 

  29. Lange HLH, Manos BE, Gothard D, Rogers LK, Bonny AE. Bone mineral density and weight changes in adolescents randomized to 3 doses of depot medroxyprogesterone acetate. J Pediatrc Adolesc Gynecol. 2016; doi:10.1016/j.jpag.2016.10.011.

    Google Scholar 

  30. Kaunitz AM, Arias R, McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception. 2008;77:67–76.

    Article  CAS  PubMed  Google Scholar 

  31. • American College of Obstetricians and Gynecologists. Depot medroxyprogesterone acetate and bone effects. Committee Opinion No. 602. Obstet Gynecol. 2014;123:1398–402. This resource reflects the opinion from ACOG, which provides clinical guidance at a national level. Based on available evidence, they do not recommend restricting the use of DMPA in reproductive-aged women on the basis of risk to bone health.

    Article  Google Scholar 

  32. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med. 2005;159:139–44.

    Article  PubMed  Google Scholar 

  33. Cundy T, Cornish J, Roberts H, Reid IR. Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception. Am J Obstet Gynecol. 2002;186:978–83.

    Article  CAS  PubMed  Google Scholar 

  34. Petitti DB, Piaggio G, Mehta S, Cravioto MC, Meirik O. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. The WHO study of hormonal contraception and bone health. Obstet Gynecol 2000; 95: 736–744.

  35. Orr-Walker BJ, Evans MC, Ames RW, Clearwater JM, Cundy T, Reid IR. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin Endocrinol. 1998;49:615–8.

    Article  CAS  Google Scholar 

  36. Viola AS, Castro S, Marchi NM, Bahamondes MV, Viola CF, Bahamondes L. Long-term assessment of forearm bone mineral density in postmenopausal former users of depot medroxyprogesterone acetate. Contraception. 2011;84:122–7.

    Article  CAS  PubMed  Google Scholar 

  37. Sarfati J, de Vernejoul MC. Impact of combined and progestogen-only contraceptives on bone mineral density. Joint Bone Spine. 2009;76:134–8.

    Article  PubMed  Google Scholar 

  38. Beerthuizen R, Van Beek A, Massai R, Makarainen L, Hout J, Bennink HC. Bone mineral density during long-term use of the progestogen contraceptive implant Implanon compared to a non-hormonal method of contraception. Hum Reprod. 2000;15:118–22.

    Article  CAS  PubMed  Google Scholar 

  39. Modesto W, DalAva N, Monteiro I, Bahamondes L. Body composition and bone mineral density in users of the etonogestrel-releasing contraceptive implant. Arch Gynecol Obstet. 2015;292:1387–91.

    Article  CAS  PubMed  Google Scholar 

  40. Bahamondes L, Monteiro-Dantas C, Espejo-Arce X, Dos Santos Fernandes AM, Lui-Filho JF, Perrotti M, Petta CA. A prospective study of the forearm bone density of users of etonogestrel- and levonorgesterel-releasing contraceptive implants. Hum Reprod. 2006;21:466–70.

    Article  CAS  PubMed  Google Scholar 

  41. Pongsatha S, Ekmahachai M, Suntornlimsiri N, Morakote N, Chaovisitsaree S. Bone mineral density in women using the subdermal contraceptive implant Implanon for at least 2 years. Int J Gynaecol Obstet. 2010;109:223–5.

    Article  CAS  PubMed  Google Scholar 

  42. Caird LE, Reid-Thomas V, Hannan WJ, Gow S, Glasier AF. Oral progestogen-only contraception may protect against loss of bone mass in breast-feeding women. Clin Endocrinol. 1994;41:739–45.

    Article  CAS  Google Scholar 

  43. Wei S, Jones G, Thomson R, Dwyer T, Venn A. Oral contraceptive use and bone mass in women aged 26–36 years. Osteoporos Int. 2011;22(1):351–5. doi:10.1007/s00198-010-1180-y. Epub 2010 Feb 27

    Article  CAS  PubMed  Google Scholar 

  44. Luukkainen T, Lahteenmaki P, Toivonen J. Levonorgestrel-releasing intrauterine device. Ann Med. 1990;22:85–90.

    Article  CAS  PubMed  Google Scholar 

  45. Bahamondes L, Espejo-Arce X, Hidalgo MM, Hidalgo-Regina C, Teatin-Juliato C, Petta CA. A cross-sectional study of the forearm bone density of long-term users of levonorgestrel-releasing intrauterine system. Hum Reprod. 2006;21:1316–9.

    Article  CAS  PubMed  Google Scholar 

  46. Bahamondes MV, Monteiro I, Castro S, Espejo-Arce X, Bahamondes L. Prospective study of the forearm bone mineral density of long-term users of the levonorgestrel-releasing intrauterine system. Hum Reprod. 2010;25:1158–64.

    Article  CAS  PubMed  Google Scholar 

  47. Yang KY, Kim YS, Ji YI, Jung MH. Changes in bone mineral density of users of the levonorgestrel- releasing intrauterine system. J Nippon Med Sch. 2012;79:190–4.

    Article  CAS  PubMed  Google Scholar 

  48. Gourlay ML, Brown SA. Clinical considerations in premenopausal osteoporosis. Arch Int Med. 2004;164:603–14.

    Article  Google Scholar 

  49. • Lopez LM, Chen M, Mullins Long S, Curtis KM, Helmerhorst FM. Steroidal contraceptives and bone fractures in women: evidence from observational studies. Cochrane Database of Systematic Reviews 2015; (7). CD009849. doi:10.1002/14651858.CD009849.pub3. This resource nicely summarizes the available evidence to date regarding hormonal contraception and risk of bone fractures. Cochran reviews are updated every few years and also take into consideration the quality of the study and evidence.

  50. Vestergaard P, Rejnmark L, Mosekilde L. Oral contraceptive use and risk of fractures. Contraception. 2006;73:571–6.

    Article  CAS  PubMed  Google Scholar 

  51. Meier C, Brauchli YB, Jick SS, Kraenzlin ME, Meier CR. Use of depot medroxyprogesterone acetate and fracture risk. J Clin Endocrin and Metab. 2010;95:4909–16.

    Article  CAS  Google Scholar 

  52. Lanza LL, McQuay LJ, Tothman KJ, Bone HG, Kaunitz AM, Harel Z, Ataher Q, Ross D, Arena PL, Wolter KD. Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture. Obstet Gynecol. 2013;121:593–600.

    Article  CAS  PubMed  Google Scholar 

  53. Kyvernitakis I, Kostev K, Nassour T, Thomasius F, Hadji P. The impact of depot medroxyprogesterone acetate on fracture risk: a case-control study from the UK. Osteoporos Int. 2017;28:291–7.

    Article  CAS  PubMed  Google Scholar 

  54. Vestergaard P, Rejnmark L, Mosekilde L. The effects of depot medroxyprogesterone actetate and intrauterine device use on fracture risk in Danish women. Contraception. 2008;78:459–64.

    Article  CAS  PubMed  Google Scholar 

  55. Pfizer. Letter to health care professionals. 2004. Available at: http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM166395.pdf. Retrieved March 1, 2017.

  56. Cundy T, Ames R, Horne A, Clearwater J, Roberts H, Gamble G, Reid IR. A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate. J Clin Endocrinol Metab. 2003;88:78–81.

    Article  CAS  PubMed  Google Scholar 

  57. Cromer BA, Lazebnik R, Rome E, Stager M, Bonny A, Ziegler J, Debanne SM. Double-blinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception. Am J Obstet Gynecol. 2005;192:42–7.

    Article  CAS  PubMed  Google Scholar 

  58. World health Organization. WHO statement on hormonal contraception and bone health. Contraception. 2006;73:443–4.

    Article  Google Scholar 

  59. • Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, Simmons KB, Pagano P, Jamieson DJ, Whiteman MK. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65(RR-3):1–104. doi:10.15585/mmwr.rr6503a1. The CDC MEC is an excellent resource to help guide providers in the safe use of contraception in women with various medical conditions and comorbidities. It takes evidence and expert opinion into consideration and is reviewed every few years based on change in the evidence.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, The Ohio State University, 395 W. 12th Ave, Rm 503, Columbus, OH, 43210, USA

    Michelle M. Isley

Authors
  1. Michelle M. Isley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michelle M. Isley.

Ethics declarations

Conflict of Interest

Michelle M. Isley declares no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Family Planning

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Isley, M.M. Progestin-Only Contraception and Bone Health. Curr Obstet Gynecol Rep 6, 94–99 (2017). https://doi.org/10.1007/s13669-017-0201-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13669-017-0201-7

Keywords

Search

Navigation